Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Crest, C.
Right arrow Articles by Baulac, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Crest, C.
Right arrow Articles by Baulac, M.
Related Collections
Right arrow All Epilepsy/Seizures
Right arrow Antiepileptic drugs
NEUROLOGY 2004;62:640-643
© 2004 American Academy of Neurology
Brief Communications

Levetiracetam in progressive myoclonic epilepsy

An exploratory study in 9 patients

C. Crest, MD*, S. Dupont, MD PhD*, E. Leguern, PhD, C. Adam, MD PhD and M. Baulac, MD

From the "Unité d’Epileptologie" (Drs. Crest, Dupont, Adam, and Baulac), INSERM EMI 0224 "Cortex et Épilepsie" (Drs. Dupont and Baulac), and INSERM U289, Neurogenetics Laboratory, Department of Genetics, Cytogenetics and Embryology (Dr. Leguern), Hôpital de la Pitié-Salpêtrière, Paris, France.

Address correspondence and reprint requests to Dr. S. Dupont, Unité d’Epileptologie, Clinique Neurologique Paul Castaigne, Hôpital de la Salpêtrière, 47, boulevard de l’Hôpital, 75651 Paris cedex 13, France; e-mail: sophie.dupont{at}psl.ap-hop-paris.fr

The authors conducted an open study of levetiracetam as add-on therapy in nine patients with well-defined progressive myoclonic epilepsies and refractory myoclonus. Myoclonus was evaluated semiquantitatively (territory, intensity, daily living activities). Five patients had improvement of their myoclonus score. Levetiracetam may benefit myoclonus in progressive myoclonic epilepsy.

Received July 30, 2003. Accepted in final form October 6, 2003.

*These authors contributed equally to the conception of the article.




This article has been cited by other articles:


Home page
 NeurologyHome page
S. Noachtar, E. Andermann, P. Meyvisch, F. Andermann, W. B. Gough, J. Schiemann-Delgado, and For the N166 Levetiracetam Study Group
Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures
Neurology, February 19, 2008; 70(8): 607 - 616.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by AAN Enterprises, Inc.